Good opportunity for admin law, bureaucracy, regulation, health law, and FDA-regulated products practitioners & scholars (just to name a few!). The Food & Drug Law Journal is convening a symposium on FDA’s relationship with other domestic regulators. From the call:

This Symposium will offer wide-ranging discussion, among scholars and practitioners, of the actual and the possible, the problematic and the productive, what has been learned, what should be studied, what might be changed, practical impediments and legal obstacles, cautions and concerns, and what the future might hold.

The Food and Drug Law Journal Symposium encourages thoughtful legal scholarship on topics that may be historical, descriptive, empirical, theoretical, or normative, as the subject dictates. Papers may consider any domestic regulators, or combination of them, from the CDC, CMS, and other sister agencies within HHS, to the Patent and Trademark Office (PTO), FTC, DOJ, SEC, Customs and Border Protection, state pharmacy boards, and federally recognized tribal governments. 

Key dates:

• Abstracts are due June 27, 2022.
• Accepted authors notified July 8, 2022.
• Draft papers due Oct. 17, 2022.
• The Symposium will take place online on Nov 3-4, 2022.

Please see the Call for Abstracts for more details.

I’m on the editorial advisory board for the Food & Drug Law Journal, so please drop me a line if you have any questions. In my experience, FDLJ is an academic journal that is very welcoming to non-academic authors. Articles do not need to be very long, just thoughtful and well done.